Literature DB >> 12791463

Local treatment of viral disease using photodynamic therapy.

Mark Wainwright1.   

Abstract

Although reports of the photodynamic inactivation of viruses appeared in 1928, long before chemotherapeutic antiviral drugs, the first clinical trial in humans-the topical treatment of herpes genitalis-did not take place until the early 1970s. Trials were discontinued due to the transformation of healthy cells and concomitant incidence of Bowen's disease in some patients, probably due to the migration of infective sections of photodamaged viral nucleic acid. With the modern development of photodynamic therapy as a cancer treatment and the use of photosensitisers in the photodecontamination of blood products, a great deal of experience has been gained, both in the minimisation of side effects in humans and in the targeting and eradication of viruses. This suggests that the photodynamic approach to a range of virus-associated infections, lesions and cancer might now be revisited with greater success.

Entities:  

Mesh:

Year:  2003        PMID: 12791463     DOI: 10.1016/s0924-8579(03)00035-9

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

Review 1.  Laser treatment of recurrent herpes labialis: a literature review.

Authors:  Carlos de Paula Eduardo; Ana Cecilia Corrêa Aranha; Alyne Simões; Marina Stella Bello-Silva; Karen Muller Ramalho; Marcella Esteves-Oliveira; Patrícia Moreira de Freitas; Juliana Marotti; Jan Tunér
Journal:  Lasers Med Sci       Date:  2013-04-13       Impact factor: 3.161

2.  Assessment of the photosensitization properties of cationic porphyrins in interaction with DNA nucleotide pairs.

Authors:  Gloria I Cárdenas-Jirón; Luis Cortez
Journal:  J Mol Model       Date:  2013-04-14       Impact factor: 1.810

3.  Advances in antimicrobial photodynamic inactivation at the nanoscale.

Authors:  Nasim Kashef; Ying-Ying Huang; Michael R Hamblin
Journal:  Nanophotonics       Date:  2017-08-01       Impact factor: 8.449

4.  Leveraging synthetic chlorins for bio-imaging applications.

Authors:  Javier Hernández-Gil; Jason S Lewis; Thomas Reiner; Charles Michael Drain; Junior Gonzales
Journal:  Chem Commun (Camb)       Date:  2020-10-20       Impact factor: 6.222

Review 5.  Photodynamic viral inactivation: Recent advances and potential applications.

Authors:  Jace A Willis; Vsevolod Cheburkanov; Giulia Kassab; Jennifer M Soares; Kate C Blanco; Vanderlei S Bagnato; Vladislav V Yakovlev
Journal:  Appl Phys Rev       Date:  2021-06       Impact factor: 19.162

6.  Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.

Authors:  Maryam Pourhajibagher; Maryam Azimi; Vahid Haddadi-Asl; Hanie Ahmadi; Mehrdad Gholamzad; Sara Ghorbanpour; Abbas Bahador
Journal:  Photodiagnosis Photodyn Ther       Date:  2021-04-07       Impact factor: 3.631

Review 7.  Photodynamic Antimicrobial Chemotherapy for Root Canal System Asepsis: A Narrative Literature Review.

Authors:  P Diogo; T Gonçalves; P Palma; J M Santos
Journal:  Int J Dent       Date:  2015-12-10

Review 8.  Antimicrobial photodynamic inactivation in nanomedicine: small light strides against bad bugs.

Authors:  Rui Yin; Tanupriya Agrawal; Usman Khan; Gaurav K Gupta; Vikrant Rai; Ying-Ying Huang; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

Review 9.  Photodynamic inactivation of mammalian viruses and bacteriophages.

Authors:  Liliana Costa; Maria Amparo F Faustino; Maria Graça P M S Neves; Angela Cunha; Adelaide Almeida
Journal:  Viruses       Date:  2012-06-26       Impact factor: 5.048

Review 10.  Can biowarfare agents be defeated with light?

Authors:  Fatma Vatansever; Cleber Ferraresi; Marcelo Victor Pires de Sousa; Rui Yin; Ardeshir Rineh; Sulbha K Sharma; Michael R Hamblin
Journal:  Virulence       Date:  2013-09-25       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.